Anti-fibrotic compounds
US11014873B2 · kind B2 · utility
1Cited by
26References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 31, 2018 |
| Grant date | May 25, 2021 |
| Priority date | — |
| Expiry date | Jan 31, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound or composition described herein. (Formula (I))
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.